Skip to main content Accessibility help
×
Home

Vasopressor and Inotrope Use in Canadian Emergency Departments: Evidence Based Consensus Guidelines

  • Dennis Djogovic (a1) (a2), Shavaun MacDonald (a2), Andrea Wensel (a2), Rob Green (a3) (a4), Osama Loubani (a3), Patrick Archambault (a5) (a6), Simon Bordeleau (a5), David Messenger (a7), Adam Szulewski (a7), Jon Davidow (a1) (a2), Janeva Kircher (a2), Sara Gray (a8), Katherine Smith (a2), James Lee (a2), Jean Marc Benoit and Dan Howes (a7)...
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Vasopressor and Inotrope Use in Canadian Emergency Departments: Evidence Based Consensus Guidelines
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Vasopressor and Inotrope Use in Canadian Emergency Departments: Evidence Based Consensus Guidelines
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Vasopressor and Inotrope Use in Canadian Emergency Departments: Evidence Based Consensus Guidelines
      Available formats
      ×

Abstract

Copyright

Corresponding author

Correspondence to: Dennis Djogovic, Room 2-124 Clinical Sciences Building, Edmonton, AB, Canada, T6G 2B7; Telephone: (780) 492-8311; Fax: (780) 492-1500; E-mail: djogovic@ualberta.ca.

References

Hide All
1. The AGREE Collaboration. (2003). Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: The AGREE project. Quality and Safety in Health Care, vol. 12, 18-23. doi: 10.1136/qhc.12.1.18.
2. Atkins, D, Eccles, M, Flottorp, S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches. The GRADE Working Group. BMC Health Serv Res 2004;4(1):38.
3. Guyatt, G, Oxman, A, Vist, G, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.
4. Jaeschke, R, Guyatt, GH, Dellinger, P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008;337:a744:327-330.
5. Guyatt, GH, Oxman, AD, Kunz, R, et al. What is “quality of evidence” and why is it important to clinicians? BMJ 2008;336:995-998.
6. Guyatt, GH, Oxman, AD, Kunz, R, et al. Going from evidence to recommendations. BMJ 2008;336:1049-1051.
7. Schünemann, HJ, Oxman, AD, Brozek, J, et al. Grading the quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106-1110.
8. Guyatt, GH, Oxman, AD, Kunz, R, et al. Incorporating considerations of resources use into grading recommendations. BMJ 2008;336:1170-1173.
9. Dellinger, RP, Levy, MM, Carlet, JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
10. GRADE working group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-1498.
11. Guyatt, G, Gutterman, D, Baumann, MH, et al. Grading strength of recommendations and quality of evidence in clinical guide- lines: Report from an American College of Chest Physicians task force. Chest 2006;129:174-181.
12. Graham, B, Regehr, G, Wright, J. Delphi as a method to establish consensus for diagnostic criteria. J of Clinic Epi 2003;56:1150-1156.
13. Hsu, CC, Sandford, BA. The Delphi Technique: Making Sense of Consensus. Practical Assessment, Research and Evaluation 2007;12(10):ISSN 1531-7714.
14. Havel, C, Arrich, J, Losert, H, et al. Vasopressors for hypotensive shock (Review). Cochrane Database of Systematic Reviews 2011, Issue 5.
15. Vasu, TS, Cavallazzi, R, Hirani, A, et al. Norepinephrine or Dopamine for Septic Shock: Systematic Review of Randomized Clinical Trials. J Intensive Care Med 2012;27:172-178.
16. De Backer, D, Aldecoa, C, Nijmi, H, et al. Dopamine versus norepinephrine in the treatment of septic shock: A meta-analysis. Crit Care Med 2012;40(3):725-730.
17. De Backer, D, Biston, P, Devriendt, J, et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. NEJM 2010;362:779-789.
18. Obritsch, MD, Jung, R, Fish, DN, et al. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 2004;38:1117-1122.
19. Cartotto, R, McGibney, K, Smith, T, et al. Vasopressin for the septic burn patient. Burns 2007;33(4):441-451.
20. Myburgh, JA, Higgins, A, Jovanovska, A, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008;34(12):2226-2234.
21. Levy, B, Perez, P, Perny, J, et al. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 2011;39:450-455.
22. Sakr, Y, Reinhart, K, Vincent, JL, et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006;34:589-597.
23. Francis, GS, Sharma, B, Hodges, M. Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J 1982;103:995-1000.
24. Cohn, SM, McCarthy, J, Stewart, RM, et al. Impact of low-dose vasopressin on trauma outcome: prospective randomized study. World J of Surg 2011;35(2):430-439.
25. Collier, B, Dossett, L, Mann, M, et al. Vasopressin use is associated with death in acute trauma patients with shock. J of Crit Care 2010;25(173):e9-e14.
26. Fangio, P, Asehnoune, K, Edouard, A, et al. Early embolization and vasopressor administration for management of life-threatening hemorrhage from pelvic fracture. J of Trauma - Injury, Infection and Crit Care 2005;58(5):978-984.
27. Haas, T, Voelckel, WG, Wiedermann, F, et al. Successful resuscitation of a traumatic cardiac arrest victim in hemorrhagic shock with vasopressin: A case report and brief review of the literature. J of Trauma - Injury, Infection and Crit Care 2004;57:177-179.
28. Plurad, DS, Talving, P, Lam, L, et al. Early vasopressor use in critical injury is associated with mortality independent from volume status. J of Trauma - Injury, Infection and Crit Care 2011;71(3):565-572.
29. Sharma, RM, Setlur, R. Vasopressin in hemorrhagic shock. Anesthesia & Analgesia 2005;101:833-834.
30. Shelly, MP, Greatorex, R, Calne, RY, et al. The physiological effects of vasopressin when used to control intra-abdominal bleeding. Intensive Care Med 1988: 526-531.
31. Sperry, JL, Minei, JP, Frankel, HL, et al. Early use of vasopressors after injury: Caution before constriction. J of Trauma - Injury, Infection and Crit Care 2008;64:9-14.
32. Wenzel, V, et al. A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin Versus Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS-Study). Available at: http://clinicaltrials.gov/ct2/show/NCT00379522?term=vitris&rank=1.
33. Boulain, T, Lanotte, R, Legras, A, et al. Efficacy of epinephrine therapy in shock complicating pulmonary embolism. Chest 1993;104:300-302.
34. Powell, B P, Simes, D. Levosimendan in acute pulmonary embolism. Anesthesia and Intensive Care 2007;35(5):771-772.
35. Jardin, F, Genevray, B, Brun-Ney, D, Margairaz, A. Dobutamine: a hemodynamic evaluation in pulmonary embolism shock. Crit Care Med 1985;13(12):1009-1012.
36. Bahloul, M, Chaari, A, Kallel, H, et al. Pulmonary Embolism in intensive care unit: predictive factors, clinical manifestations and outcome. Ann of Thoracic Med 2010;5(2):97-103.
37. Hata, M, Sezai, A, Iida, M, et al. A non-operative survival case of an 84 year old patient with type A acute aortic dissection complicated by pulseless tamponade. Annals of Thoracic Cardiovascular Surgery 2006;12(4):297-299.
38. Kim, R, Siouffi, S, Silberstein, TA, et al. Management and clinical outcomes of acute cardiac tamponade complicating electrophysiologic procedures: A single-center case series. Pacing and Clinical Electrophysiology 2009; Jun 33:667-674.
39. Schmitto, JD, Hein, S, Brauer, A, et al. Perioperative myocardial infarction after cesarean section in a young woman with hypertrophic obstructive cardiomyopathy. Acta Anaesthesiologica scandinavica 2008;52(4):578-579.
40. Auer, J, Berent, R, Weber, T, et al. Catecholamine therapy inducing dynamic left ventricular outflow tract obstruction. Int J of Cardiology 2005;101:325-328.
41. Deimi, R, Hess, W, Bahlmann, E. Primary cesarean section. Use of phenylephrine during anesthesia in a patient with hypertrophic cardiomyopathy. Der Anaesthesist 2000;4(6):1-5.
42. Beale, RJ, Hollenberg, SM, Vincent, J, et al. Vasopressor and inotropic support in septic shock: An evidence-based review. Crit Care Med 2004;32(S11):S455-S465.
43. Hollenberg, SM, Ahrens, TS, Annane, D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004;32(9):1928-1948.
44. Ihle, BU. Clinical practice guidelines for improving outcomes in sepsis. Heart, Lung and Circ 2008;17(S4):S26-S31.
45. Robinson, A. What's the best vasopressor in septic shock? Emerg Med J 2010;27(7):556-558.
46. Dellinger, RP, Levy, MM, Rhodes, A, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41(2):580-637.
47. Patel, GP, Grahe, JS, Sperry, M, et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 2010;33(4):375-380.
48. Povoa, PR, Carneiro, AH, Ribeiro, OS, et al. Influence of vasopressor agent in septic shock mortality. Results from the Portuguese community-acquired sepsis study (SACiUCI study). Crit Care Med 2009;37(2):410-416.
49. Boulain, T, Runge, I, Bercault, N, et al. Dopamine therapy in septic shock: Detrimental effect on survival? J of Crit Care 2009;24(4):575-582.
50. Xu, B, Oziemski, P. Dopamine versus noradrenaline in septic shock. Australasian Med J 2011;4(10):571-574.
51. Seguin, P, Bellissant, E, Le Tulzo, Y, et al. Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clin Pharma and Therapeutics 2002;71(5):381-388.
52. Levy, B, Bollaert, PE, Charpentier, C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997;23(3):282-287.
53. Annane, D, Vignon, P, Renault, A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: A randomised trial. Lancet 2007;370(9588):676-684.
54. Mahmoud, K, Ammar, A. Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock. Indian J of Crit Care Med 2012;16(2):75-80.
55. Jain, G, Singh, DK. Comparison of phenylephrine and norepinephrine in the management of dopamine-resistant septic shock. Indian J of Crit Care Med 2010;14(1):29-34.
56. Morelli, A, Ertmer, C, Rehberg, S, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, control trial. Crit Care 2008;12(6):R143.
57. Morelli, A, Lange, M, Ertmer, C, et al. Short-term effects of phenylephrine on systemic and regional hemodynamics in patients with septic shock: a crossover pilot study. Shock 2008;29(4):446-451.
58. Thiele, RH, Nemergut, EC, Lynch, C. The clinical implications of isolated alpha1 adrenergic stimulation. Anesthesia & Analgesia 2011;113(2):297-304.
59. Lauzier, F, Levy, B, Lamarre, P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: A randomized clinical trial. Intensive Care Med 2006;32(11):1782-1789.
60. Luckner, G, Dunser, MW, Jochberger, S, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005;33(11):2659-2666.
61. Russell, JA, Walley, KR, Singer, J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. New Engl J Med 2008;358(9):877-887.
62. Oliveira, S. Early vasopressin application in shock. Crit Care. Conference: Sepsis 2011 Beijing, China. Conference Start: 20111026. Conference End: 20111028. Conference Publication 2011: (Var.Pagings), 15 S2.
63. Lam, S, Bauer, S. Association between catecholamine dose at the onset of arginine vasopressin for septic shock and intensive care unit mortality. CritCare Med. Conference: 39th Critical Care Congress of the Society of Critical Care Medicine, Miami Beach, FL, United States. Conference Start: 20100109. Conference End: 20100113. Conference Publication: (Var.Pagings), 37(S12), A243.
64. Andresen, M, Dougnac, A, Diaz, O, et al. Use of methylene blue in patients with refractory septic shock: Impact on hemodynamics and gas exchange. J of Crit Care 1998;13(4):164-168.
65. Kirov, MY, Evgenov, OV, Evgenov, NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 2001;29(10):1860-1867.
66. Paciullo, CA, Horner, DM, Hatton, K, et al. Methylene blue for the treatment of septic shock. Pharmacotherapy 2010;30(7):702-715.
67. Kwok, E, Howes, D. Use of methylene blue in sepsis: A systematic review. J of Intensive Care Med 2006;21(6):359-363.
68. Wilkman, E, Kaukonen, M, Pettila, V, et al. The association between inotrope treatment and 90-day mortality in patients with septic shock. Intensive Care Med. Conference: 24th Annual Congress of the European Society of Intensive Care Medicine, ESICM LIVES 2011 Berlin, Germany. Conference Start: 20111001. Conference End: 20111005. Conference Publication: (Var.Pagings), 37, S146.
69. Vincent, J, Roman, A, Kahn, RJ. Dobutamine administration in septic shock: Addition to a standard protocol. Crit Care Med 1990;18(7):689-693.
70. Hai-Bo, Q, Yi, Y, Shao-Xia, Z, et al. Renal effect of dopamine, norepinephrine, epinephrine, or norepinephrine-dobutamine in septic shock. Crit Care and Shock 2002;5(1):9-14.
71. De Backer, D, Creteur, J, Dubois, M, et al. The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 2006;34(2):403-408.
72. Enrico, C, Kanoore Edul, V, Vazquez, AR, et al. Systemic and microcirculatory effects of dobutamine in patients with septic shock. J of Crit Care 2012;27(6):630-638.
73. Hernandez, G, Regueira, T, Bruhn, A, et al. Effects of dobutamine on microcirculation, regional and peripheral perfusion in septic shock patients: A randomized double blind crossover trial. Preliminary report. Intensive Care Med. Conference: 24th Annual Congress of the European Society of Intensive Care Medicine, ESICM LIVES 2011 Berlin, Germany. Conference Start: 20111001. Conference End: 20111005. Conference Publication: (Var.Pagings), 37, S92.
74. Rivers, E, Nguyen, B, Havstad, S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345(19):1368-1377.
75. Ploumis, A, Yadlapalli, N, Fehlings, MG, et al. A systematic review of the evidence supporting a role for vasopressor support in acute SCI. Spinal Cord 2010;48(5):356-362.
76. Auzinger, G, Wendon, J. Intensive care management of acute liver failure. Current Opinion Crit Care 2008;14(2):179-188.
77. Gines, P, Fernandez, J, Durand, F, Saliba, F. Management of critically ill cirrhotic patients. J of Hepatology 2012;56(S1):S13-S24.
78. Jalan, R. Acute liver failure: current management and future prospects. J of Hepatology 2005;42:S115-S123.
79. Lee, W, Larson, A, Stravitz, T. AASLD Position Paper: The Management of Acute Liver Failure: Update 2011. Hepatology 2011;54(3):1-22.
80. Larson, AM, (2011). Acute Liver Failure, in Schiff's Diseases of the Liver, 11th Ed. (eds ER Schiff, WC Maddrey, MF Sorrell), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781119950509.ch19.
81. Rinella, ME, Sanyal, A. Intensive management of hepatic failure. Semin Respir Crit Care Med 2006;27(3):241-261.
82. Patton, J, Misel, M, Gish, RG. Acute liver failure in adults: an evidence-based management protocol for clinicians. Gastroenterol Hepatol 2012;8(3):161-212.
83. Stravitz, RT, Kramer, AH, Davern, T, et al. Intensive care of patients with acute liver failure: recommendations of the US Acute Liver Failure Study Group. Crit Care Med 2007;35(11):2498-2508.
84. Olson, JC, Wendon, JA, Kramer, DJ, et al. Intensive care of the patient with cirrhosis. Hepatology 2011;54(5):1864-1872.
85. Wagener, G, Kovalevskaya, G, Minhaz, M, et al. Vasopressin deficiency and vasodilatory state in end-stage liver disease. J Cardiothorac Vasc Anesth 2011;25(4):665-670.
86. Sheikh, A, Shehata, YA, Brown, G, et al. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. Cochrane Database of Systematic Reviews 2012,4.
87. Brown, S, Blackman, K, Stenlake, V, et al. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J 2004;21(2):149-154.
88. Dewachter, P, Jouan-Hureaux, V, Lartaud, I, et al. Comparison of arginine vasopressin, terlipressin, or epinephrine to correct hypotension in a model of anaphylactic shock in anesthetized brown norway rats. Anesthesiology 2006;104(4):734-741.
89. Dewachter, P, Raeth-Fries, I, Jouan-Hureaux, V, et al. A comparison of epinephrine only, arginine vasopressin only, and epinephrine followed by arginine vasopressin on the survival rate in a rat model of anaphylactic shock. Anesthesiology 2007;106(5):977-983.
90. Zheng, F, Barthel, G, Chantal, M, et al. Methylene blue and epinephrine, a synergistic association for anaphylactic shock treatment in anesthetized brown norway rats. Euro Jof Anaesthesiology. Conference: European Anaesthesiology Congress, EUROANAESTHESIA 2011 Amsterdam Netherlands. Conference Start: 20110611. Conference End: 20110614. Conference Publication: (Var.Pagings), 28, 192.
91. Hebard, S, Ball, AJ. Role of alpha agonists in treating anaphylaxis. BMJ 2008;337(7661):67.
92. Heytman, M, Rainbird, A. Use of alpha-agonists for management of anaphylaxis occurring under anaesthesia: Case studies and review. Anaesthesia 2004;59(12):1210-1215.
93. Hussain, AM, Yousuf, B, Khan, MA, et al. Vasopressin for the management of catecholamine-resistant anaphylactic shock. Singapore Med J 2008;49(9):e225-e228.
94. Evora, PR, Roselino, C, Schiaveto, PM. Methylene blue in anaphylactic shock. AnnEmerg Med 1997;30(2):240.
95. Meng, L, Williams, EL. Case report: Treatment of rocuronium-induced anaphylactic shock with vasopressin. Can J of Anesthesia 2008;55(7):437-440.
96. Ponniah, M, Saravanan, PA, Jeslin, L, et al. Role of norepinephrine in anaphylaxis. J of Anaesthesiology Clin Pharma 2009;25(2):244-245.
97. Oliveira, N, Duarte, NM, Vicente, WV, et al. Methylene blue: an effective treatment for contrast medium-induced anaphylaxis. Med Sci Monit 2003;9(11):CS102-CS106.
98. Schummer, C, Wirsing, M, Schummer, W. The pivotal role of vasopressin in refractory anaphylactic shock. Anesthesia & Analgesia 2008;107(2):620-624.
99. Schummer, W, Schummer, C, Wippermann, J, et al. Anaphylactic shock: is vasopressin the drug of choice? Anesthesiology 2004;101(4):1025-1027.
100. Stocche, R, Garcia, LV, Paulino Dos Reis, M, et al. Methylene blue to treat anaphylaxis during anesthesia: case report. Revista Brasileira de Anestesiologia 2004;54(6):809-814.
101. Williams, S, Denault, A, Pellerin, R. Vasopressin for treatment of shock following aprotinin administration. Can J of Anesthesia 2004;51(2):169-172.
102. Part 10.6 , : Anaphylaxis. Circulation 2005;112(24 S):143-145.
103. Brown, S. The pathophysiology of shock in anaphylaxis. Immuno and Allergy Clinics of N Am 2007;27(2):165-175.
104. Kemp, S, Lockey, R, Simons, F. Epinephrine: The drug of choice for anaphylaxis. A statement of the world allergy organization. Allergy 2008;63(8):1061-1070.
105. Lieberman, P, Nicklas, R, Oppenheimer, J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update [Abstract]. The J of Allergy and Clin Immuno 2010;126(3):477-480.e42.
106. Simons, F, Ardusso, L, Bilo, M, et al. World Allergy Organization. World allergy organization anaphylaxis guidelines: summary. The J of Allergy and ClinImmuno 2011;127(3):587-593.
107. Soar, J, Perkins, G, Abbas, G, et al. European resuscitation council guidelines for resuscitation 2010 Section 8. Cardiac arrest in special circumstances: electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation 2010;81(10):1400-1433.
108. Matsumoto, S, Hagiwara, S, Kusaka, R, et al. Catecholamine-resistant shock and hypoglycaemic coma after cardiotomy in a patient with unexpected isolated ACTH deficiency. J Anesth 2011;25(3):431-434.
109. Picolos, MK, Nooka, A, Davis, AB, et al. Bilateral adrenal hemorrhage: an overlooked cause of hypotension. J Emerg Med 2007:Feb 32(2):167-169.
110. Serrano, N, Jimenez, JJ, Brouard, MT, et al. Acute adrenal insufficiency after cardiac surgery. Crit Care Med 2000;28(2):569-570.
111. Bunker, N, Higgins, D. Peripheral administration of vasopressin for catecholamine-resistant hypotension complicated by skin necrosis. Crit Care Med 2006;34(3):935; author reply 935-936, doi: 10.1097/01.CCM.0000202202.85087.37.
112. Putland, M, Kerr, D, Kelly, AM. Adverse events associated with the use of intravenous epinephrine in emergency department patients presenting with severe asthma. Ann Emerg Med 2006;47(6):559-563. doi: 10.1016/j.annemergmed.2006.01.022.
113. Tran, DQ, Finlayson, RJ. Use of stellate ganglion block to salvage an ischemic hand caused by the extravasation of vasopressors. Reg Anesth Pain Med 2005;30(4):405-408.
114. Davies, AG, Russell, WC, Thompson, JP. Extravasation and tissue necrosis secondary to central line infusions. Anaesthesia 2003;58(8):820-821.
115. Kahn, JM, Kress, JP, Hall, JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 2002;30(8):1899-1901.
116. Stier, PA, Bogner, MP, Webster, K, et al. Use of subcutaneous terbutaline to reverse peripheral ischemia. Am J Emerg Med 1999;17(1):91-94.
117. Chen, JL, O'Shea, M. Extravasation injury associated with low-dose dopamine. Ann Pharmacother 1998;32(5):545-548.
118. Perrot, J, Eyraud, P, Guy, C, et al. Terlipressin-induced mucocutaneous skin necrosis: Report of four cases. Eur J Dermatol 1996;6(1):14-18.
119. Cooper, BE. High-dose phentolamine for extravasation of pressors. Clin Pharm 1989;8(10):689.
120. Reed, WP, Newman, KA, Applefeld, MM, et al. Drug extravasation as a complication of venous access ports. Ann Intern Med 1985;102(6):788-790.
121. Anderson, JR, Johnston, GW. Development of cutaneous gangrene during continuous peripheral infusion of vasopressin. Br Med J (Clin Res Ed) 1983;287(6406):1657-1658.
122. Wormser, GP, Kornblee, LV, Gottfried, EB. Cutaneous necrosis following peripheral intravenous vasopressin therapy. Cutis 1982;29(3):249-252.
123. Crocker, MC. Intravascular guanethidine in the treatment of extravasated vasopressin. N Engl J Med 1981;304(23):1430.
124. Mogan, GR, Wormser, GP, Gottfried, EB. Infected gangrene. A serious complication of peripheral vasopressin administration. Am J Gastroenterol 1980;73(5):426-429.
125. Hoff, JV, Beatty, PA, Wade, JL. Dermal necrosis from dobutamine. N Engl J Med 1979;300(22):1280.
126. Lynch, DJ, Key, JC, White, RR. 4th. Management and prevention of infiltration and extravasation injury. SurgClin North Am 1979;59(5):939-949.
127. Upton, J, Mulliken, JB, Murray, JE. Major intravenous extravasation injuries. Am J Surg 1979;137(4):497-506.
128. Gaze, NR. Tissue necrosis caused by commonly used intravenous infusions. Lancet 1978;2(8086):417-419.
129. Greenwald, RA, Rheingold, OJ, Chiprut, RO, et al. Local gangrene: A complication of peripheral pitressin therapy for bleeding esophageal varices. Gastroenterology 1978;74(4):744-746.
130. Boltax, RS, Dineen, JP, Scarpa, FJ. Gangrene resulting from infiltrated dopamine solution. N Engl J Med 1977;296(14):823.
131. Ebels, T, van der Heide, JN. Dopamine-induced ischaemia. Lancet 1977;2(8041):762.
132. Stetson, JB, Reading, GP. Avoidance of vascular complications associated with the use of dopamine. Can Anaesth Soc J 1977;24(6):727-733.
133. Oglesby, JE, Baugh, JH. Tissue necrosis due to norepinephrine. Am J Surg 1968;115(3):408-412.
134. Weeks, PM. Ischemia of the hand secondary to levarterenolbitartrate extravasation. methods of management. JAMA 1966;196(3):288-290.
135. Fritz, H, Hagstam, KE, Lindqvist, B. Local skin necrosis after intravenous infusion of norepinephrine, and the concept of endotoxinaemia. A clinical study on 10 cases. Acta Med Scand 1965;178(4):403-416.
136. Jaconelli, J. Massive gangrene of the lower limb following use of continuous noradrenaline intravenous infusion. Med J Aust 1965;1(3):79-80.
137. Grewal, RS. Gangrene following infusion of norepinephrine. report of a case. J Int Coll Surg 1964;41:275-277.
138. Mitchinson, MJ, Gresham, GA. Epidermal necrosis due to nor-adrenaline. Br J Dermatol 1964;76:495-496.
139. Mehrotra, MP, Kishore, B. Local tissue necrosis and cutaneous gangrene following intravenous infusion of noradrenaline. J Assoc Physicians India 1963;11:639-643.
140. Zucker, G, Eisinger, RP, Floch, MH, et al. Treatment of shock and prevention of ischemic necrosis with levarterenol-phentolamine mixtures. Circulation 1960;22:935-937.
141. Close, AS, Frackelton, WH. Cutaneous necrosis due to norepinephrine: Analysis of reported cases and surgical treatment. Wis Med J 1958;57(3).
142. Bryant, MF, Berben, JY, Howard, JM. Prevention of norepinephrine (levophed) sloughs. J Med Assoc Ga 1957;46(7):336-339.
143. De Alvarez, RR, Nyhus, LM, Merendino, KA, et al. Tissue necrosis associated with intravenous nor-epinephrine administration. Am Surg 1957;23(7):619-635.
144. Hardy, SB, Hamilton, JM. Treatment of tissue necrosis following intravenous use of norepinephrine. Plast and Reconstr Surg 1957 (1946);20(5):360-365.
145. Heard, GE. Skin necrosis in nor-adrenaline therapy. Br J Clin Pract 1957;11(4):260-262.
146. Pelner, L. Treatment of localischemia due to levarterenol (levophed) leakage with piperoxan. J Am Med Assoc 1957;165(5):444-447.
147. Zucker, G. Use of phentolamine to prevent necrosis due to levarterenol. J Am Med Assoc 1957;163(16):1477-1479.
148. McGinn, JT, Schluger, J. Skin sloughs associated with levophed; pathogenesis, prevention and treatment. Am J Surg 1956;92(4):594-602.
149. Perlow, S, Shapiro, RA. Skin necrosis following intravenous use of norepinephrine; report of six cases. Am J Surg 1956;92(4):566-570.
150. Selke, O Jr. Histamine iontophoresis to prevent tissue necrosis following levarterenol extravasation. Arch Phys Med Rehabil 1956;37(10):643-646.
151. Wall, CA, Hanlon, CR. Necrosis following administration of levarterenol during shock. AMA Arch Surg 1956;72(2):332-335.
152. Hall, B. Recovery of patient in prolonged shock after arterenoltherapy. J Am Med Assoc 1955;157(8):653-654.
153. Hardie, GH, Hunter, DC. Skin necrosis with the intravenous use of norepinephrine. Med Bull (Ann Arbor) 1955;21(7):213-219.
154. Humphreys, J, Johnston, JH, Richardson, JC. Skin necrosis following intravenous noradrenaline. Br Med J 1955;2(4950):1250-1252.
155. Irvin, CWJ, Bunch, GH. Spontaneous rupture of the esophagus, with a note on tissue necrosis from nor-epinephrine. Am J Med 1954;17(4):571-577.
156. Kepes, ER, Haimovichi, H, Simon, B. Skin necrosis following intravenous use of norepinephrine; case reports. Surgery 1954;36(4):822-825.
157. Peirce, E, Polley, VB. Necrosis following intravenous use of neo-synephrine. N Engl J Med 1954;250(3):114-115. doi: 10.1056/NEJM195401212500305.
158. Bergmann, H. Advantages and disadvantages of prolonged use of nor-epinephrine. Int J Anesth 1953;1(1):29-34.
159. Crawford, ES, Haynes, BW. The use of nor-epinephrine in the treatment of hypotension associated with common surgical conditions. Am Surg 1953;19(2):191-201.
160. Uricchio, JF, Calenda, DG, Cutts, FB. Ulceration on the skin following intravenous use of arterenol. J Am Med Assoc 1953;152(7):607-608.
161. Greenwald, HP, Gootnick, A, Luger, NM, et al. Tissue necrosis following subcutaneous infiltration with nor-epinephrine; report of two cases. N Engl J Med 1952,246(7):252-253. doi: 10.1056/NEJM195202142460704.
162. Kurland, GS, Malach, M. The clinical use of norepinephrine in the treatment of shock accompanying myocardial infarction and other conditions. N Engl J Med 1952;247(11):383-389. doi: 10.1056/NEJM195209112471102.
163. Moen, TC, Sarwark, JF. Compartment syndrome following intraosseousinfusion. Orthopedics 2008;31(8):815.
164. Wechselberger, G, Radauer, W, Schimpl, G, et al. Lower limb salvage in a 7-month-old infant using free tissue transfer. J Pediatr Surg 2011;46(9):1852-1854. doi: 10.1016/j.jpedsurg.2011.06.037.
165. Stoll, E, Golej, J, Burda, G, et al. Osteomyelitis at the injection site of adrenalin through an intraosseous needle in a 3-month-old infant. Resuscitation 2002;53(3):315-318.
Type Description Title
UNKNOWN
Supplementary materials

Djogovic Supplementary Material
Appendix

 Unknown (270 KB)
270 KB
PDF
Supplementary materials

Djogovic Supplementary Material
Djogovic Supplementary Material

 PDF (1.8 MB)
1.8 MB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed